Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on September 5, 2023. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's continued listing status.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metric disclosed is the stock price performance:
- Stock Price Deficiency: The average closing price of the Common Stock over the 30 trading days ending September 1, 2023, fell below the required $1.00 per share minimum.
Material Changes
The material event reported is the receipt of a formal Notice from Nasdaq indicating a failure to satisfy the Minimum Bid Requirement (Listing Rule 5550(a)(2)). This notice has no immediate effect on the trading of the stock but initiates a compliance period.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The company has 180 calendar days (until March 4, 2024) to regain compliance.
- Compliance Criteria: The closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days within the compliance period.
- Secondary Compliance Period: If the initial period is unsuccessful, the company may be eligible for an additional 180-day period, contingent on meeting other listing standards (e.g., market value of publicly held shares).
- Risks: There is no assurance the company will regain compliance. Failure to cure the deficiency could result in delisting. The company retains the right to appeal a delisting determination to a Hearings Panel.
- Management Action: Management intends to actively monitor the stock price and evaluate available options to regain compliance.
Investor Verification Checklist
- Verify the current trading price of Salarius Pharmaceuticals (SLRX) to assess proximity to the $1.00 threshold.
- Monitor subsequent filings for updates on the company's plan to regain compliance (e.g., reverse stock split proposals).
- Review the company's most recent 10-K or 10-Q for liquidity and cash runway, as this 8-K does not contain financial data.
- Confirm the company's market value of publicly held shares to determine eligibility for a second compliance period if needed.